At the 2018 Genitourinary Cancers Symposium, lead investigator Alison Jane Birtle, MD, MBBS, MRCP, FRCR, presented the results of the phase 3 POUT clinical trial, which showed that adjuvant chemotherapy had impressive gains in the disease-free survival and metastasis-free survival in upper-tract urothelial cancer
Because of the growing prevalence of cancer survivorship, the financial burden of cancer is becoming increasingly overwhelming for patients not only immediately after a cancer diagnosis, but often many years after treatment, said K. Robin Yabroff, PhD, MBA, of the American Cancer Society.
According to findings from a national representative sample presented at the 2018 Cancer Survivorship Symposium, fear of cancer recurrence is prevalent among cancer survivors, but may only be experienced by a minority of patients.
The American Society of Clinical Oncology and the National Comprehensive Cancer Network collaborated to jointly develop a new guideline to help clinicians recognize and manage the range of side effects from immune checkpoint inhibitors.
New results from the phase 3 QuANTUM-R trial showed that quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation.
The FDA accelerated the approval of brigatinib (Alunbrig), a new generation of oral ALK inhibitor, for the treatment of patients with ALK-positive metastatic NSCLC who do not tolerate or have had an inadequate response to crizotinib..
To sign up for our newsletter or print publications, please enter your contact information below.
